



Practitioner's Docket No. NEB-198-PUS

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Samuelson, James C.; Xu, Shuang-yong

Application No.: 10/501,196

Group No.: 1645

Filed: January 9, 2003

Examiner: not yet assigned

For: Alteration of Restriction Endonuclease Specificity by Genetic Selection

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

CERTIFICATION UNDER 37 C.F.R. " 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

X with sufficient postage as first class mail.

37 C.F.R. § 1.10*

G as "Express Mail Post Office to Addressee"

Mailing Label No. _____ (mandatory)

TRANSMISSION

G facsimile transmitted to the Patent and Trademark Office, (703) _____

Signature

Leslie Goldberg


(type or print name of person certifying)

Date: November 5, 2004

* Only the date of filing (' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" (' 1.10) or facsimile transmission (' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

BEST AVAILABLE COPY

Date: November 5, 2004



Harriet M. Strimpel
Registration No. 37,008
New England Biolabs, Inc.
32 Tozer Road
Beverly, MA 01915
978-927-5054
Customer No. 28986



10 Rnd POT/PTO 08 NOV 2004

Practitioner's Docket No. NEB-198-PUS

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: James C. Samuelson, Shuang-yong Xu

Application No.: 10/501,196

Group No.: 1645

Filed: January 9, 2003

Examiner: not yet assigned

For: Alteration of Restriction Endonuclease Specificity by Genetic Selection

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)
2. Copies of Listed Information Items Accompanying This Statement
3. Identification of Person(s) Making This Information Disclosure Statement

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

X with sufficient postage as first class mail.

37 C.F.R. § 1.10*

G as "Express Mail Post Office to Addressee"

Mailing Label No. _____ (mandatory)

TRANSMISSION

G facsimile transmitted to the Patent and Trademark Office, (703) _____ - _____

Signature

Leslie Goldberg

(type or print name of person certifying)

Date: November 5, 2004

* Only the date of filing ('1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under '1.8 continues to be taken into account in determining timeliness. See '1.703(f). Consider "Express Mail Post Office to Addressee" ('1.10) or facsimile transmission ('1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Section 1. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)

(Insert form(s) PTO/SB/08A [Form 6-2] and/or form(s) PTO/SB/08B [Form 6-2.1].)

Section 2. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement with the exception of U.S. patents and published applications.


AA (no copy enclosed); BA-CG

Section 3. Identification of Person Making This Information Disclosure Statement


The person making this certification is:

- a. the practitioner who signs below on the basis of the information in the practitioner's file.

Date: November 5, 2004



Harriet M. Strimpel
Registration No. 37,008
New England Biolabs, Inc.
32 Tozer Road
Beverly, MA 01915
978-927-5054
Customer No. 28986



SECTION 2. FORMS PTO/SB/08A and 08B (formerly Form PTO-1449)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Samuelson et al. Attorney Docket: NEB-198-PUS
Serial No: 10/501,196 Art Group Unit: 1645
Date Filed: 01/09/2003 Examiner Name: Not yet assigned
Invention: Alternation of Restriction Endonucleases

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS					
Examiner Initials	Reference Number	Document Number	Issue Date	Inventor	Class/Subclass
	AA	US 5,498,535			

OTHER DOCUMENTS			
Examiner Initials	Reference Number	Author	Title of Article, Title of Journal, Volume Number, Page Numbers, Date
	BA	Arkin et al.	Proc. Natl. Acad. Sci. USA 89:7811-7815 (1992).
	BB	Arnold et al.	Curr. Opin. Biotechnol. 4:450-455 (1993).
	BC	Bingle et al.	Can. J. Microbiol. 39:70-80 (1993).
	BD	Cadwell et al.	PCR Methods Applic. 2:29-33 (1992).
	BE	Delegrave et al.	Biotechnology Res. 11:1548-1552 (1993).
	BF	Dorner et al.	J. Mol. Biol. 285:1515-1523 (1999).
	BG	Dorner et al.	Nucl. Acids Res. 22:1068-1074 (1994).
	BH	Engelrecht et al.	Science 227:1345-1347 (1985).
	BI	Flores et al.	Gene 157:295-301 (1995).
	BJ	Heitman et al.	Proteins 7:185-197 (1990).
	BK	Heitman et al.	EMBO J. 9:3369-3378 (1990).
	BL	Heitman et al.	Bioessays 14:445-454 (1992).
	BM	Hoffman et al.	Proc. Natl. Acad. Sci. USA 82:5107-5111 (1985).
	BN	Horton et al.	J. Biol. Chem. 273:21721-21729 (1998).
	BO	Ivanenko et al.	J. Biol. Chem. 379:459-465 (1998).
	BP	Iwasaki et al.	J. Bacteriol. 172:6268-6273 (1990).
	BQ	Lanio et al.	Protein Eng. 13:275-281 (2000).
	BR	Lanio et al.	J. Mol. Biol. 283:59-69 (1998).
	BS	Leung et al.	Technique 1:11-15 (1989).
	BT	Lewis et al.	J. Bacteriol. 174:5110-5116 (1992).
	BU	Long-McGie et al	Biotechnol. Bioeng. 68:121-125 (2000).
	BV	Metcalfe et al.	Gene 129:17-25 (1993).
	BW	Morrison et al.	Biotechniques 14:454-457 (1993).
	BX	Muir et al.	J. Mol. Biol. 274:722-737 (1997).



10 RASHI 55777C 08 NOV 2004

BY	Newman et al.	Science 269:5656-663 (1995).
CA	Newman et al.	Nature 368:660-664 (1994).
CB	Pingoud et al.	Nucl. Acids Res. 29:3705-3727 (2001).
CC	Roberts et al.	Nucl. Acids Res. 29:268-269 (2001).
CD	Stemmer et al.	Proc. Natl. Acad. Sci. USA 91:10747-10751 (1994).
CE	Thompson et al.	Nucl. Acids Res. 16:9687-9705 (1988).
CF	Ward et al.	Mol. Gen. Genet. 203:468-478 (1986).
CG	Whitaker et al.	J. Mol. Biol. 285:1525-1536 (1999).
	Xu et al.	J. Biol. Chem. 266:4425-4429 (1991).

Examiner Signature: _____

Date Considered: _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation *if not* in conformance and not considered. Include copy of this form with next communication to applicant.